BiotechTube
OpenCell Technologies

OpenCell Technologies

San Francisco, United States· Est.
opencelltech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $26.5M

Overview

OpenCell Technologies is a private, pre-revenue biotech tools company founded in 2018, based in San Francisco. It has developed a proprietary 'Soft Poration' platform that uses controlled flow-induced shear to mechanically and temporarily porate cells on a single-cell basis for superior intracellular delivery. The technology addresses a critical bottleneck in utilizing hard-to-transfect cells for research and therapeutic development. With a strong IP portfolio of 8 issued patents, the company is positioned to serve the growing cell and gene therapy market with scalable tools for both research and bioprocessing workflows.

Drug Delivery

Technology Platform

Soft Poration™: An electromechanical, microfluidic intracellular delivery platform that uses controlled flow-induced shear to temporarily porate cells on a single-cell basis for high-efficiency delivery of nucleic acids, proteins, and other cargo into difficult-to-transfect cells.

Funding History

2
Total raised:$26.5M
Series A$22M
Seed$4.5M

Opportunities

The rapid growth of the cell and gene therapy market creates a massive need for scalable, gentle, and efficient cell engineering tools.
OpenCell's platform is uniquely suited to address the bottleneck of transfecting hard-to-manipulate primary cells, positioning it to capture significant value in both research and clinical manufacturing workflows.
Its technology flexibility also allows expansion into adjacent applications like protein delivery and nanoparticle delivery.

Risk Factors

Key risks include slower-than-expected adoption of a novel platform in a conservative market, technical challenges in scaling the microfluidic system for robust GMP manufacturing, and competition from large, established players with extensive resources and customer relationships.
As a private company, it also faces financing risk and dependence on achieving milestones to secure future capital.

Competitive Landscape

OpenCell competes with established transfection method providers, including chemical reagents (e.g., Thermo Fisher, Mirus Bio), electroporation systems (e.g., MaxCyte, Lonza), and other physical methods. Its primary differentiator is claimed superior performance on difficult-to-transfect cells like primary human stem cells. It also competes in the enabling technology space for cell therapy manufacturing against companies developing alternative cell processing and engineering platforms.

More companies in Drug Delivery & Formulation →More companies in United States →